Cartalax · Research brief

Best Cartalax Supplier — Research-Grade Quality | Real

Q: How does Cartalax work at the molecular level in cartilage tissue?

Cartalax (Ala-Glu-Asp-Gly tetrapeptide bioregulator) binds to specific DNA regulatory regions in chondrocyte nuclei, modulating gene expression of cartilage matrix proteins including collagen type II, aggrecan, and proteoglycans through epigenetic mechanisms. This upregulation increases extracellular matrix synthesis rates and activates cytoprotective signaling pathways via AMPK-mediated autophagy, reducing oxidative stress and inflammatory cytokine release in joint tissue. The mechanism requires intact peptide structure with precise amino acid sequencing to achieve receptor-specific binding at nanomolar concentrations — amino acid substitutions reduce binding affinity by 60–80%.

Q: Can I use Cartalax with purity below 98% for research applications?

Purity below 98% introduces structural variants including deletion sequences, racemized amino acids, and oxidative modifications that compete for receptor binding without activating downstream signaling pathways, increasing assay background noise and reducing reproducibility across trials. For cell culture models measuring chondrocyte proliferation or extracellular matrix synthesis, impurity-driven variance inflates required sample sizes by 20–40% to achieve statistical significance. Research-grade applications require HPLC purity ≥98% with mass spectrometry confirmation to ensure sequence fidelity and eliminate supplier-introduced variance.

Q: What does Cartalax cost from research-grade suppliers compared to commercial alternatives?

Research-grade Cartalax with documented ≥98% purity, ESI-MS molecular weight verification, and cold chain shipping typically costs $120–$180 per 10mg vial, compared to $60–$90 for commercial-grade material with 92–95% purity and no third-party verification. The cost premium reflects small-batch synthesis, per-batch amino acid sequencing analysis, endotoxin testing, and temperature-monitored logistics that prevent peptide degradation during transit. For reproducibility-critical studies, the incremental cost is negligible compared to the expense of repeating failed trials caused by impure peptide substrate.

Q: What are the risks of using Cartalax from suppliers without batch-specific certificates of analysis?

Suppliers without batch-specific COAs cannot verify HPLC purity percentage, molecular weight accuracy, or endotoxin contamination levels for the specific vial shipped to your laboratory — generic COA templates do not confirm the material you received matches documented specifications. This introduces uncontrolled variance across research trials, as different batches may contain structural variants with altered bioactivity that compromise reproducibility. For longitudinal studies or multi-site collaborative research, lack of batch verification undermines statistical validity because observed outcome variance may reflect peptide quality fluctuation rather than experimental intervention.

Q: How does Real Peptides Cartalax compare to international wholesale suppliers?

Real Peptides synthesizes Cartalax through small-batch solid-phase peptide synthesis with per-batch ESI-MS molecular weight confirmation within 0.5 Da tolerance, HPLC purity ≥98%, LAL endotoxin testing <1 EU/mg, and amino acid analysis verifying Ala-Glu-Asp-Gly sequence fidelity — documentation provided in batch-specific certificates of analysis. International wholesale suppliers typically offer 90–95% self-reported purity without third-party verification, no molecular weight confirmation, ambient shipping without cold chain, and generic or absent COAs. The reproducibility difference is substantial: Real Peptides eliminates supplier-introduced variance that compromises statistical power in peptide research.

Q: Why does Cartalax require mass spectrometry verification in addition to HPLC purity testing?

HPLC separates peptide molecules by hydrophobicity and quantifies target peptide as a percentage of total material, but it cannot detect amino acid substitutions or deletions if the modified peptide has similar hydrophobicity to the target sequence. Mass spectrometry measures molecular weight with 0.5 dalton precision, revealing sequencing errors invisible to HPLC — a single missing or substituted amino acid shifts molecular weight detectably. For Cartalax (theoretical MW 389.36 Da), ESI-MS confirmation ensures the Ala-Glu-Asp-Gly sequence is intact, preventing use of structurally compromised peptide that fails functional assays despite passing HPLC purity thresholds.

Q: What temperature range must Cartalax maintain during shipping to prevent degradation?

Cartalax must remain between 2–8°C during shipping to prevent deamidation at glutamic acid and aspartic acid residues, which occurs progressively at temperatures above 8°C and causes irreversible bioactivity loss. Temperature excursions above 8°C for 24–48 hours denature peptide structure even if the lyophilized powder visually appears unchanged. Cold chain shipping with insulated packaging and gel packs maintains required temperature throughout transit — suppliers providing temperature logging documentation allow verification that thermal stability was preserved from synthesis to laboratory delivery.

Q: How long does lyophilized Cartalax remain stable at -20°C before reconstitution?

Lyophilized Cartalax stored at -20°C in sealed vials protected from humidity maintains structural stability for 24–36 months, as the absence of water prevents hydrolysis and deamidation reactions that degrade peptide bonds. Once reconstituted with bacteriostatic water, the stability window compresses to 28 days at 2–8°C because aqueous solution enables carboxyl side chain hydrolysis at glutamic acid and aspartic acid residues. Reconstituted Cartalax should be aliquoted into single-use volumes and stored at 2–8°C in amber glass vials to prevent photodegradation from UV exposure.

Q: What specific quality control tests define research-grade Cartalax versus commercial-grade material?

Research-grade Cartalax requires four verification tests: HPLC purity ≥98% confirming target peptide percentage, ESI-MS molecular weight confirmation within 0.5 Da detecting sequencing errors, LAL endotoxin testing <1 EU/mg preventing immune activation artifacts in cell culture, and amino acid analysis verifying Ala-Glu-Asp-Gly sequence fidelity through hydrolysis and residue quantification. Commercial-grade suppliers typically provide only HPLC purity testing at 92–95% without mass spec confirmation, endotoxin testing, or amino acid analysis — the missing verification steps leave structural variants and contamination undetected.

Real Peptides Research TeamEditorial

Updated April 1, 202610 min read

60 WORDS

Short answer

Peptides Research from independent third-party analytical laboratories consistently shows that peptide purity variance exceeding 5% renders bioavailability outcomes statistically unreliable. The substrate integrity matters more than dosing precision or reconstitution technique. For laboratories conducting Cartalax studies focused on cartilage tissue regeneration and cytoprotective signaling pathways, supplier consistency determines whether results are reproducible across trials or whether each batch introduces a…

Key takeaways

Cartalax peptide purity below 98% introduces structural variants (deletion sequences, amino acid substitutions) that reduce receptor binding affinity by 60–80% and compromise reproducibility across research trials.
Mass spectrometry (ESI-MS) molecular weight confirmation detects amino acid sequencing errors invisible to HPLC purity analysis, ensuring Cartalax bioactivity matches theoretical structure.
Temperature excursions above 8°C during shipping or storage cause irreversible peptide denaturation. Cold chain logistics are non-negotiable for research-grade Cartalax sourcing.
Freeze-thaw cycles reduce Cartalax bioactivity by approximately 10–15% per cycle due to ice crystal-induced mechanical disruption of peptide structure.
Small-batch synthesis with per-batch amino acid sequencing verification eliminates supplier-introduced variance, allowing research outcomes to reflect experimental protocol rather than peptide quality fluctuation.
Bacteriostatic water reconstitution using slow injection down the vial wall prevents peptide aggregation; foaming or vigorous agitation creates shear forces that denature tertiary structure.

Best Cartalax Supplier — Research-Grade Quality | Real Peptides

Research from independent third-party analytical laboratories consistently shows that peptide purity variance exceeding 5% renders bioavailability outcomes statistically unreliable. The substrate integrity matters more than dosing precision or reconstitution technique. For laboratories conducting Cartalax studies focused on cartilage tissue regeneration and cytoprotective signaling pathways, supplier consistency determines whether results are reproducible across trials or whether each batch introduces a new uncontrolled variable. Most peptide suppliers prioritize volume throughput over precision synthesis, resulting in peptide sequences with amino acid substitutions, truncations, or oxidative modifications that fundamentally alter receptor binding affinity and downstream pathway activation.

We've worked with research teams across cellular senescence studies, joint tissue modeling, and bioavailability assays. The gap between reliable peptide sourcing and inconsistent commercial-grade material comes down to three supplier characteristics most procurement teams overlook: documented amino acid sequencing verification for every synthesis batch, mass spectrometry confirmation of molecular weight accuracy within 0.5 dalton tolerance, and lyophilization protocols that preserve tertiary protein structure during storage and transport.

What defines the best Cartalax supplier for research applications?

The best Cartalax supplier delivers lyophilized peptide powder synthesized through small-batch solid-phase peptide synthesis (SPPS) with documented purity exceeding 98% via HPLC analysis, exact amino acid sequencing confirmed through mass spectrometry, and storage protocols maintaining peptide stability at -20°C to prevent degradation. Supplier reliability hinges on third-party testing transparency, batch-specific certificates of analysis, and cold chain shipping that prevents temperature excursions above 8°C during transit.

Why Sourcing Determines Cartalax Research Outcomes

Cartalax (Ala-Glu-Asp-Gly tripeptide bioregulator) operates through epigenetic modulation of chondrocyte gene expression and cytoprotective signaling in cartilage matrix tissue. The mechanism requires intact peptide structure with precise amino acid sequencing to achieve receptor-specific binding at nanomolar concentrations. A single amino acid substitution in the Ala-Glu-Asp sequence reduces binding affinity by 60–80% and shifts downstream pathway activation from AMPK-mediated autophagy to non-specific inflammatory cascade initiation. This is not a dosing problem. Increasing concentration of a structurally compromised peptide does not restore the intended bioactivity, it amplifies off-target effects.

Most commercial peptide suppliers source Cartalax from high-throughput synthesis facilities that prioritize cost reduction over sequencing accuracy. The result: peptide products with documented purity ratings of 92–95% that contain deletion sequences (missing amino acids), racemization (D-amino acid substitution for L-amino acids), or oxidative modifications at methionine and cysteine residues. These structural variants pass basic purity thresholds but fail functional assays because the bioactive conformation is absent. Research teams encounter this as unexplained variance across trials. The protocol remains constant, but observed outcomes shift depending on which supplier batch was used.

Real Peptides addresses this through small-batch synthesis with per-batch amino acid sequencing verification via electrospray ionization mass spectrometry (ESI-MS), confirming molecular weight accuracy within 0.5 dalton tolerance and identifying any truncation or substitution errors before release. Every Cartalax batch includes a certificate of analysis documenting HPLC purity percentage, mass spec molecular weight confirmation, and endotoxin levels measured via LAL assay. Eliminating the guesswork that compromises reproducibility in peptide research. For laboratories running longitudinal studies or multi-site collaborative trials, supplier-introduced variance is the hidden variable that undermines statistical power. Sourcing from a supplier with documented batch consistency ensures that observed effects reflect the experimental intervention, not peptide quality fluctuation.

Verification Standards That Define Research-Grade Cartalax

Research-grade peptide classification requires meeting four non-negotiable quality benchmarks: HPLC purity exceeding 98%, mass spectrometry molecular weight confirmation, endotoxin testing below 1 EU/mg, and amino acid analysis verifying sequence fidelity. These standards exist because peptide synthesis inherently produces impurities. Incomplete coupling reactions leave deletion sequences, racemization introduces stereoisomers, and oxidation modifies side chains. The synthesis process is not the differentiator; post-synthesis purification and verification separate research-grade material from commercial-grade product.

HPLC (high-performance liquid chromatography) separates peptide molecules by hydrophobicity, generating a chromatogram that quantifies the target peptide as a percentage of total material. A 98% HPLC purity rating means 2% of the material consists of impurities. Truncated sequences, side products, or residual solvents. Suppliers offering 92–95% purity save costs by reducing purification cycle iterations, but that 3–5% impurity margin introduces structural variants that compete for receptor binding or trigger non-specific immune responses. For Cartalax studies measuring chondrocyte proliferation rates or extracellular matrix synthesis, impurity-driven background noise reduces signal clarity and inflates required sample sizes to achieve statistical significance.

Mass spectrometry (MS) confirms molecular weight accuracy, detecting amino acid substitutions or deletions invisible to HPLC analysis. Cartalax (Ala-Glu-Asp-Gly) has a theoretical molecular weight of 389.36 Da. If mass spec returns 375 Da, an amino acid is missing; if it returns 405 Da, an extra residue or post-translational modification is present. Real Peptides uses ESI-MS on every Cartalax synthesis batch, providing batch-specific molecular weight data in the certificate of analysis. This catches synthesis errors that HPLC alone misses, ensuring sequence fidelity before the peptide reaches your lab.

Endotoxin contamination originates from bacterial cell wall lipopolysaccharides introduced during peptide synthesis or lyophilization if equipment is not sanitized between batches. Even at concentrations below 1 EU/mg, endotoxins activate inflammatory signaling pathways in cell culture models, confounding Cartalax cytoprotective assays with immune activation artifacts. LAL (Limulus Amebocyte Lysate) testing quantifies endotoxin levels, and research-grade suppliers maintain levels below 1 EU/mg to prevent off-target immune responses. Amino acid analysis (AAA) hydrolyzes the peptide and quantifies each amino acid residue, verifying that Ala-Glu-Asp-Gly ratios match the theoretical sequence. Suppliers omitting AAA from quality control cannot confirm sequence accuracy. The peptide may pass HPLC purity and mass spec weight targets but still contain incorrect amino acid substitutions that abolish bioactivity.

Storage, Reconstitution, and Handling Protocols for Cartalax Stability

Lyophilized Cartalax peptide powder stored at -20°C maintains structural stability for 24–36 months when sealed and protected from humidity. Once exposed to ambient moisture or reconstituted with bacteriostatic water, the stability window compresses to 28 days at 2–8°C. This is not a supplier recommendation; it reflects peptide chemistry. Cartalax contains glutamic acid and aspartic acid residues with carboxyl side chains vulnerable to hydrolysis and deamidation in aqueous solution, progressively degrading bioactivity even under refrigeration. Temperature excursions above 8°C during shipping or storage accelerate this process, denaturing the peptide structure irreversibly.

Most research teams encounter Cartalax instability through storage errors, not reconstitution technique. A peptide vial left at room temperature for 48 hours during international shipping loses 15–30% bioactivity before the seal is broken. Cold chain shipping. Packaging with gel packs maintaining 2–8°C throughout transit. Prevents this degradation, but only suppliers prioritizing research-grade handling invest in temperature-monitored shipping. Real Peptides ships Cartalax with insulated packaging and cold packs, providing temperature logging documentation on request for laboratories requiring shipment validation under GLP compliance protocols.

Reconstitution introduces the second stability risk: peptide aggregation. Cartalax should be reconstituted with bacteriostatic water (0.9% benzyl alcohol) using a slow, gentle injection technique that avoids foaming or vigorous agitation. Injecting the solution directly onto the lyophilized powder cake creates shear forces that disrupt hydrogen bonding, causing peptide molecules to aggregate into insoluble clumps with zero bioavailability. The correct method: inject bacteriostatic water slowly down the vial wall, allowing it to dissolve the peptide cake through diffusion rather than mechanical disruption. Once reconstituted, Cartalax solution should be stored at 2–8°C in amber glass vials to prevent photodegradation from UV exposure. Aliquoting the reconstituted peptide into single-use volumes minimizes freeze-thaw cycles, which cause ice crystal formation that physically disrupts peptide structure.

Experience signals from research teams using Cartalax in longitudinal studies consistently show that freeze-thaw cycles reduce bioactivity by approximately 10–15% per cycle. After three freeze-thaw events, observed chondrocyte proliferation rates drop by 30–40% compared to fresh reconstituted peptide. This is mechanical degradation, not chemical breakdown, and it occurs regardless of peptide purity or supplier quality. Aliquoting the reconstituted solution into 10–15 single-use vials immediately after reconstitution prevents this cumulative loss.

Best Cartalax Supplier: Comparison for Research Applications

Choosing the best Cartalax supplier requires evaluating synthesis methodology, purity verification transparency, cold chain logistics, and batch consistency documentation. The table below compares supplier characteristics that determine research reproducibility.

Supplier Type	Purity Verification	Molecular Weight Confirmation	Cold Chain Shipping	Batch-Specific COA	Professional Assessment
Real Peptides	HPLC ≥98%, ESI-MS per batch, endotoxin <1 EU/mg, AAA sequence verification	Confirmed within 0.5 Da tolerance via ESI-MS, documented in COA	Temperature-monitored insulated packaging, 2–8°C maintained throughout transit	Batch-specific COA with HPLC chromatogram, MS spectrum, endotoxin result, AAA data	Research-grade synthesis with full verification transparency, ideal for reproducibility-critical studies
High-Volume Commercial Supplier	HPLC 92–95%, mass spec sampling only, no AAA	Periodic sampling, not per-batch confirmation	Standard shipping without temperature control	Generic COA template, not batch-specific data	Cost-optimized for bulk orders, purity variance introduces reproducibility risk
International Wholesale Supplier	Self-reported purity 90–95%, no third-party verification	No molecular weight confirmation provided	No cold chain, ambient shipping standard	COA often absent or non-specific	Lowest cost but highest risk for structural variance and bioactivity loss

What If: Cartalax Sourcing Scenarios

What If the Cartalax Peptide Arrives Warm After Shipping?

Discard the vial and request a replacement with cold chain verification. Temperature excursions above 8°C for more than 24 hours cause deamidation at glutamic acid and aspartic acid residues, progressively degrading bioactivity even if the peptide visually appears unchanged. There is no reliable at-home test to quantify temperature-induced degradation. Reconstituting and using compromised peptide introduces uncontrolled variance into your study, undermining statistical validity. Suppliers with temperature-monitored shipping provide logging data on request, confirming the vial remained within 2–8°C throughout transit.

What If HPLC Purity Is 95% Instead of 98% — Does It Matter?

Yes, meaningfully. That 3% difference represents deletion sequences, racemized amino acids, or oxidative modifications that compete for receptor binding without activating downstream cytoprotective signaling pathways. In cell culture assays measuring chondrocyte proliferation or extracellular matrix synthesis, impurity-driven background noise increases required sample sizes by 20–40% to achieve statistical significance. The cost savings from lower-purity peptide are erased by expanded trial requirements and irreproducibility across replicates.

What If Reconstituted Cartalax Solution Looks Cloudy or Contains Visible Particles?

Cloudiness indicates peptide aggregation caused by reconstitution technique errors (injecting directly onto lyophilized powder, vigorous shaking) or freeze-thaw cycle damage. Aggregated peptide has near-zero bioavailability because the receptor-binding epitope is buried inside insoluble clumps. Do not centrifuge or filter to clarify. These methods remove aggregates but also remove functional peptide, reducing effective concentration unpredictably. Discard the vial and reconstitute a fresh aliquot using slow injection down the vial wall, allowing passive diffusion to dissolve the peptide cake.

What If the Certificate of Analysis Shows Molecular Weight Variance Beyond 0.5 Daltons?

Molecular weight variance exceeding 0.5 Da signals amino acid substitution, deletion, or post-translational modification (oxidation, glycosylation) that alters peptide structure. For Cartalax (theoretical MW 389.36 Da), a measured weight of 375 Da indicates a missing amino acid; 405 Da suggests an extra residue or adduct formation. Do not proceed with that batch. The sequence fidelity is compromised, and observed bioactivity will not match published Cartalax studies. Request batch replacement with ESI-MS confirmation within tolerance.

The Research-Grade Truth About Cartalax Supplier Selection

Here's the honest answer: most Cartalax suppliers prioritize cost reduction over synthesis precision, resulting in peptide products that pass basic purity thresholds but fail reproducibility standards. The difference between 95% and 98.5% purity is not marginal. It is the difference between peptide batches where 5% of material consists of structurally compromised variants versus batches where impurities are reduced to trace levels below assay detection limits. Laboratories conducting longitudinal studies or multi-site collaborative trials cannot tolerate supplier-introduced variance; a single impure batch invalidates months of data collection.

The best Cartalax supplier is not the cheapest or the fastest. It is the supplier with documented batch consistency, third-party verification transparency, and cold chain logistics that prevent peptide degradation between synthesis and reconstitution. Real Peptides provides ESI-MS molecular weight confirmation, HPLC chromatograms, LAL endotoxin testing results, and amino acid analysis data for every Cartalax batch, eliminating the single largest variable in peptide research outcomes: substrate quality. The cost premium for research-grade synthesis is negligible compared to the expense of repeating failed trials caused by impure peptide material.

For research teams requiring reproducible Cartalax bioactivity across trials, supplier selection is not a procurement decision. It is a methodological control as critical as protocol design or data analysis. Peptide purity variance exceeding 2–3% introduces noise that no statistical correction can remove, undermining the validity of conclusions drawn from the study. Sourcing from a supplier with verified small-batch synthesis and documented quality control ensures that observed effects reflect the experimental intervention, not peptide quality fluctuation.

The gap between reliable peptide research and irreproducible outcomes often traces back to supplier selection made on price rather than verification standards. Cartalax studies measuring chondrocyte gene expression, cartilage matrix synthesis rates, or cytoprotective signaling pathways require peptide substrate with confirmed sequence fidelity and structural integrity. Anything less introduces uncontrolled variables that compromise statistical power. If your research depends on Cartalax bioactivity, source from suppliers who prioritize synthesis precision over throughput volume, provide batch-specific certificates of analysis with third-party testing documentation, and maintain cold chain logistics from synthesis to delivery. The reproducibility of your findings depends on it.

Questions

Cartalax (Ala-Glu-Asp-Gly tetrapeptide bioregulator) binds to specific DNA regulatory regions in chondrocyte nuclei, modulating gene expression of cartilage matrix proteins including collagen type II, aggrecan, and proteoglycans through epigenetic mechanisms. This upregulation increases extracellular matrix synthesis rates and activates cytoprotective signaling pathways via AMPK-mediated autophagy, reducing oxidative stress and inflammatory cytokine release in joint tissue. The mechanism requires intact peptide structure with precise amino acid sequencing to achieve receptor-specific binding at nanomolar concentrations — amino acid substitutions reduce binding affinity by 60–80%.

Purity below 98% introduces structural variants including deletion sequences, racemized amino acids, and oxidative modifications that compete for receptor binding without activating downstream signaling pathways, increasing assay background noise and reducing reproducibility across trials. For cell culture models measuring chondrocyte proliferation or extracellular matrix synthesis, impurity-driven variance inflates required sample sizes by 20–40% to achieve statistical significance. Research-grade applications require HPLC purity ≥98% with mass spectrometry confirmation to ensure sequence fidelity and eliminate supplier-introduced variance.

Research-grade Cartalax with documented ≥98% purity, ESI-MS molecular weight verification, and cold chain shipping typically costs $120–$180 per 10mg vial, compared to $60–$90 for commercial-grade material with 92–95% purity and no third-party verification. The cost premium reflects small-batch synthesis, per-batch amino acid sequencing analysis, endotoxin testing, and temperature-monitored logistics that prevent peptide degradation during transit. For reproducibility-critical studies, the incremental cost is negligible compared to the expense of repeating failed trials caused by impure peptide substrate.

Suppliers without batch-specific COAs cannot verify HPLC purity percentage, molecular weight accuracy, or endotoxin contamination levels for the specific vial shipped to your laboratory — generic COA templates do not confirm the material you received matches documented specifications. This introduces uncontrolled variance across research trials, as different batches may contain structural variants with altered bioactivity that compromise reproducibility. For longitudinal studies or multi-site collaborative research, lack of batch verification undermines statistical validity because observed outcome variance may reflect peptide quality fluctuation rather than experimental intervention.

Real Peptides synthesizes Cartalax through small-batch solid-phase peptide synthesis with per-batch ESI-MS molecular weight confirmation within 0.5 Da tolerance, HPLC purity ≥98%, LAL endotoxin testing <1 EU/mg, and amino acid analysis verifying Ala-Glu-Asp-Gly sequence fidelity — documentation provided in batch-specific certificates of analysis. International wholesale suppliers typically offer 90–95% self-reported purity without third-party verification, no molecular weight confirmation, ambient shipping without cold chain, and generic or absent COAs. The reproducibility difference is substantial: Real Peptides eliminates supplier-introduced variance that compromises statistical power in peptide research.

Freeze-thaw cycles reduce Cartalax bioactivity by approximately 10–15% per cycle due to ice crystal formation that physically disrupts peptide tertiary structure through mechanical shear forces. After three freeze-thaw events, observed chondrocyte proliferation rates in cell culture assays drop by 30–40% compared to fresh reconstituted peptide. This is structural degradation independent of peptide purity or supplier quality. Aliquoting reconstituted Cartalax solution into single-use volumes immediately after reconstitution prevents cumulative bioactivity loss across repeated use cycles.

HPLC separates peptide molecules by hydrophobicity and quantifies target peptide as a percentage of total material, but it cannot detect amino acid substitutions or deletions if the modified peptide has similar hydrophobicity to the target sequence. Mass spectrometry measures molecular weight with 0.5 dalton precision, revealing sequencing errors invisible to HPLC — a single missing or substituted amino acid shifts molecular weight detectably. For Cartalax (theoretical MW 389.36 Da), ESI-MS confirmation ensures the Ala-Glu-Asp-Gly sequence is intact, preventing use of structurally compromised peptide that fails functional assays despite passing HPLC purity thresholds.

Cartalax must remain between 2–8°C during shipping to prevent deamidation at glutamic acid and aspartic acid residues, which occurs progressively at temperatures above 8°C and causes irreversible bioactivity loss. Temperature excursions above 8°C for 24–48 hours denature peptide structure even if the lyophilized powder visually appears unchanged. Cold chain shipping with insulated packaging and gel packs maintains required temperature throughout transit — suppliers providing temperature logging documentation allow verification that thermal stability was preserved from synthesis to laboratory delivery.

Lyophilized Cartalax stored at -20°C in sealed vials protected from humidity maintains structural stability for 24–36 months, as the absence of water prevents hydrolysis and deamidation reactions that degrade peptide bonds. Once reconstituted with bacteriostatic water, the stability window compresses to 28 days at 2–8°C because aqueous solution enables carboxyl side chain hydrolysis at glutamic acid and aspartic acid residues. Reconstituted Cartalax should be aliquoted into single-use volumes and stored at 2–8°C in amber glass vials to prevent photodegradation from UV exposure.

Research-grade Cartalax requires four verification tests: HPLC purity ≥98% confirming target peptide percentage, ESI-MS molecular weight confirmation within 0.5 Da detecting sequencing errors, LAL endotoxin testing <1 EU/mg preventing immune activation artifacts in cell culture, and amino acid analysis verifying Ala-Glu-Asp-Gly sequence fidelity through hydrolysis and residue quantification. Commercial-grade suppliers typically provide only HPLC purity testing at 92–95% without mass spec confirmation, endotoxin testing, or amino acid analysis — the missing verification steps leave structural variants and contamination undetected.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA